ETAP-Lab is a French preclinical CRO recognised for 30 years for its high-level research services – in Dermatology, Neurology, Gastroenterology and Cardiology – that support its customers’ pharmacological research for the benefit of human health.

Thanks to the HealthCare innovation France 2030 plan, we participate to BIO in the French delegation made up with companies at the forefront of innovation. Our French partners that support us in this Business adventure are CCI International Grand Est, Business France Healthcare and Eurobiomed.

This year our company will be represented by Dr. Jérôme BERNARD and Dr. Sandra ROBELET during BIO’s One-on-One Partnering™.

With the recent incorporation of SYNCROSOME in late 2023, the company can now propose a brand-new in vivo Parkinson’s disease model as well as a large preclinical cardiorespiratory offer, hence strengthening the global in vivo model portfolio.

ETAP-Lab’s, along with its brands SYNCROSOME & STROK@LLIANCE, can accelerate, derisk and support preclinical development thanks to relevant & translatable in vitro and in vivo models.

The company proposes a consolidated portfolio of models in Dermatology (for inflammatory pathologies & wound healing…), in Neurology (for stroke, neurodegenerative disease like Parkinson’s and Alzheimer’s, and psychopharmacology), in Gastroenterology (for gastrointestinal & metabolic disturbances) and in Cardiology (for Pulmonary Arterial Hypertension and heart failure – HFrEF, HFpEF, …). Using state-of-the-art techniques, advanced imaging tools (MRI, PET-Scan) and our histology and immunohistochemistry platforms, ETAP-Lab offers better predictability of therapies and medical devices efficacy.

Beyond expertise, the flexible and human-sized organization allow to design and operate tailored drug efficacy studies to fit client’s needs.